Alzheimer's - Dementia, Author Interviews, Cost of Health Care, Medicare, UCLA / 15.10.2024

MedicalResearch.com Interview with: [caption id="attachment_64014" align="alignleft" width="150"]Frank F. Zhou  |  he/himMD Candidate, Class of 2025 David Geffen School of Medicine at UCLA Frank F Zhou[/caption] Frank F. Zhou  |  he/him MD Candidate, Class of 2025 David Geffen School of Medicine at UCLA MedicalResearch.com: What is the background for this study? What is Lecanemab used for?  How is it given to patients? Response: Lecanemab is a new infusion therapy for Alzheimer's disease. Its dosing is based on each patient's body weight (10 mg/kg every two weeks), but the drug is only available in 500 mg and 200 mg single-use vials, meaning that any leftover drug in vials must be thrown away. Given that lecanemab is expected to cost Medicare billions of dollars each year, we hypothesized that discarded drug could result in significant wasteful spending.
Annals Internal Medicine, Author Interviews, Gender Differences, UCLA / 25.04.2024

MedicalResearch.com Interview with: [caption id="attachment_61597" align="alignleft" width="150"]Yusuke Tsugawa, MD, PhDAssociate Professor of Medicine & Health Policy and Management, UCLA Director of Data Core, UCLA Department of Medicine Statistics Core Division of General Internal Medicine and Health Services Research David Geffen School of Medicine at UCLA Los Angeles, CA 90024 Dr. Tsugawa[/caption] Yusuke Tsugawa, MD, PhD Associate Professor of Medicine & Health Policy and Management, UCLA Director of Data Core, UCLA Department of Medicine Statistics Core Division of General Internal Medicine and Health Services Research David Geffen School of Medicine at UCLA Los Angeles, CA 90024   MedicalResearch.com: What is the background for this study? Response: Prior studies have found that female and male physicians practice medicine differently. For example, female physicians are, on average, more likely to abide by clinical guidelines and spend more time listening to patients. However, evidence was limited as to whether such differences have clinically meaningful impact on patients’ health outcomes, which was the aim of this study.
Author Interviews, Neurological Disorders, Science, UCLA / 29.09.2023

MedicalResearch.com Interview with: [caption id="attachment_60886" align="alignleft" width="125"]@dgsomucla Dr. Sofroniew[/caption] Michael Sofroniew, MD, PhD Professor UCLA School of Medicine MedicalResearch.com: What is the background for this study? How did this study differ from your previous work on this topic? Response: After spinal cord injuries, nerve fibers that are damaged do not spontaneously regrow across injury sites. In previous studies, our group of collaborators identified a combination of interventions that could stimulate damaged nerve fibers to regrow for short distances across injuries, but we found that in spite of this short distance regrowth there was no recovery of functions. The present study examined what type of regrowth might be necessary to re-establish functions.
Author Interviews, General Medicine, Health Care Systems, Heart Disease, JAMA / 26.06.2023

MedicalResearch.com Interview with: [caption id="attachment_60551" align="alignleft" width="200"]Dan P. Ly, MD, PhD, MPPPhysician and an Assistant Professor Division of General Internal Medicine and Health Services Research David Geffen School of Medicine at UCLA Dr. Ly[/caption] Dan P. Ly, MD, PhD, MPP Physician and an Assistant Professor Division of General Internal Medicine and Health Services Research David Geffen School of Medicine at UCLA MedicalResearch.com: What is the background for this study? Response: Cognitive biases, or ways of thinking that may deviate from rationality, are thought to influence physician decision-making, but there has been little large-scale evidence of their existence clinically. There is some large-scale evidence of the availability heuristic, under which the likelihood of an event is affected by how easily it comes to mind, but there’s little large scale evidence of other cognitive biases affecting physicians. 
Author Interviews, Lyme, Race/Ethnic Diversity, UCLA / 18.10.2021

MedicalResearch.com Interview with: Dan P. Ly M.D., Ph.D., M.P.P. [caption id="attachment_58262" align="alignleft" width="200"]Dr. Dan P. Ly Dr. Dan P. Ly[/caption] Division of General Internal Medicine and Health Services Research David Geffen School of Medicine at UCLA Los Angeles, CA  MedicalResearch.com: What is the background for this study? Response: Lyme disease presents first on the skin with the classic “bull’s-eye” rash. But such rashes in Black patients aren’t well-represented in medical textbooks. This may lead to physicians not recognizing such rashes in Black patients. As a result, Black patients are more likely to present with later complications of Lyme disease when first diagnosed such as neurologic complications.  
Author Interviews, Breast Cancer, JAMA, USPSTF / 12.09.2019

MedicalResearch.com Interview with: [caption id="attachment_46135" align="alignleft" width="200"]Dr. Carol Mangione M.D., M.S.P.H., F.A.C.P Ronald Reagan UCLA Medical Center Division Chief of General Internal Medicine and Health Services Research Professor of Medicine. Barbara A. Levey, MD, and Gerald S. Levey, MD Endowed chair in medicine David Geffen School of Medicine University of California Dr. Mangione[/caption] Dr. Carol Mangione, M.D., M.S.P.H., F.A.C.P. Division Chief of General Internal Medicine and Health Services Research Professor of Medicine Barbara A. Levey, MD, and Gerald S. Levey, MD, endowed chair in Medicine David Geffen School of Medicine University of California Los Angeles Professor of public health at the UCLA Fielding School of Public Health.  MedicalResearch.com: What is the background for this study? Response: We all want to find better ways to help prevent breast cancer, a disease that impacts the lives of too many women in the United States each year. Fortunately, the Task Force found there are steps that women at increased risk can take to reduce their chances of developing breast cancer.
Author Interviews, Cancer Research, JAMA, MRI, Prostate Cancer, UCLA / 12.09.2019

MedicalResearch.com Interview with: [caption id="attachment_51263" align="alignleft" width="150"]Rajiv Jayadevan, MD Department of Urology UCLA Dr. Jayadevan[/caption] Rajiv Jayadevan, MD and  Leonard S. Marks, MD Department of Urology UCLA MedicalResearch.com: What is the background for this study? Response: Men with low risk prostate cancer often enter “active surveillance” programs. These programs allow patients to defer definitive treatment (and avoid their associated side effects) until more aggressive disease is detected, if at all. Patients typically undergo a “confirmatory biopsy” 6 to 12 months after diagnosis to verify that their disease is low risk, and then undergo repeat biopsies every 1 to 2 years. These biopsies have traditionally been performed under the guidance of transrectal ultrasonography. Transrectal ultrasonography is unable to accurately visualize tumors within the prostate, necessitating that biopsy cores be obtained systematically from all parts of the prostate. MRI-ultrasonography fusion biopsy is a newer technology that has been shown to characterize biopsy findings more accurately than transrectal ultrasonography, leading to improved disease detection. This technology also allows us to visualize tumors within the prostate, and directly target these tumors during a biopsy session.